RxDoctor Payments Data

Simrita Sidhu, MD

Internal Medicine · Spring Hill, FLNPI 1619938834

Payments from drug & device makers

$937in general payments, 2019–2025

Across 53 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$379
  • AstraZeneca$205
  • Pfizer$94
  • Johnson & Johnson$81
  • Amarin Pharma, Inc.$62
  • Lilly USA, LLC$36
  • plus $81 from 4 others

What the payments were for

  • Food & beverage$937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$937 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$162,233
Medicare patients
213
Services billed
2,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$129,188
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$46,359
JardianceEmpagliflozin24$37,326
FarxigaDapagliflozin Propanediol29$32,386
JanuviaSitagliptin Phosphate23$29,292
OzempicSemaglutide18$18,063
MyrbetriqMirabegron16$17,974
Breo ElliptaFluticasone/Vilanterol12$5,907
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm19$5,592
CholestyramineCholestyramine (With Sugar)19$5,401
Dabigatran EtexilateDabigatran Etexilate Mesylate18$5,366
Atorvastatin Calcium501$4,625
Levothyroxine Sodium376$4,570
Gabapentin168$3,563
Albuterol Sulfate HfaAlbuterol Sulfate102$2,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$129,188124 claims
GSKTrelegy Ellipta, Breo Ellipta$379$52,26549 claims
AstraZenecaFarxiga$205$32,38629 claims
Astellas Pharma US IncMyrbetriq$31$17,97416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Spring Hill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →